Rubella virus protein (RV E1, RV E2, RV capsid)

Rubella virus proteins include three principal structural proteins—capsid, envelope glycoprotein E1, and envelope glycoprotein E2—as well as two nonstructural proteins (p90, p150)[3][4][5][1]. The capsid protein interacts with the viral RNA genome to form the nucleocapsid, and possesses anti-apoptotic functions critical to viral replication[6]. The E1 glycoprotein is the immunodominant antigen, mediating receptor attachment and membrane fusion—key steps in viral cell entry[1][4][5][2]. E2 acts as a chaperone for E1 and assists in virion assembly[1][2]. Nonstructural proteins participate in viral genome replication. Infection leads to rubella (German measles), which is mild in children but can cause severe congenital defects if acquired during pregnancy[3][4][5]. Prevention currently relies on the highly effective live attenuated vaccine[3][4][5]. No drugs are approved targeting these individual proteins, but their unique roles make them attractive for future antiviral therapy development[3][1][6]. Note: For most research and clinical purposes, specific rubella virus proteins such as "Rubella virus envelope glycoprotein E1" should be used as canonical molecular targets rather than the ambiguous "Rubella virus proteins"[1][3][5].

Other names

Rubella virus structural proteinsRubella virus capsid proteinRubella virus E1 glycoproteinRubella virus E2 glycoproteinRV E1RV E2RV capsid

Induction of neutralizing antibodies preventing viral entry and fusion (vaccine/E1 glycoprotein). Inhibition of viral replication or assembly (hypothetical direct antivirals targeting capsid or nonstructural proteins). Anti-apoptotic inhibition (capsid protein blocks host apoptosis to favor viral replication).